Hi Titus,
wont be any decision until mid next year by the FDA.
QRX in my opinion stuffed up first time around by not submitting the trial on rate of respiratory depression.
Odd thing was it is one of MOXDUOs advantages as I see it.
Iam still holding and am very positive considering the last 6 such submissions for similar opiates got passed on second time round.Actually 5 out 6.
REGARDS,
sales and revenue examples, page-4
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
